Product Detail

Ephedrine Sulfate in 0.9% Sodium Chloride Injection 50 mg/10 mL

Unit of Sale NDC 14789-0250-10

Size
10 mL vials
Unit of Sale
10 vials per carton
Type
Rx
Storage
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]
Active
50 mg ephedrine sulfate
Inactives
Sodium chloride
Preservative-free
Yes
Latex-free

Yes*

Allergen-free
Yes

*Vial closure is not made with natural rubber latex

Order directly through your wholesaler or from Customer Service at (888) 806-4606

Unit of sale NDC 14789-0250-10

Size: 10 mL vials

Unit of sale: 10 vials per carton

Under the Controlled Substances Act (CSA), your state may require additional licensing for dispensing EMERPHED® ready-to-use ephedrine.

For questions, please contact customer service at 888‑806‑4606.

Wholesaler
Item Number
Cardinal
5644521
McKesson
1538644
Morris & Dickson
903617
Amerisource Bergen
10235817

The Nexus Difference

Committed to Quality — From Molecules to Medicine

Starting with the source

  • After years of research & development, EMERPHED® completed a rigorous FDA approval process
  • Consumers and health professionals rely on the drug approval process for verification of safety, effectiveness, and quality1

Partnering with the right CMO*

  • Based in North America and Europe—highly regulated markets with strong compliance histories

*Contract Manufacturing Organization

Applying extra quality assurance

  • EMERPHED® is terminally sterilized which means the product is sterilized in its final container, ensuring a high level of sterility assurance, aligning with FDA guidelines and cGMP2
  • Testing does not occur just once—every single batch goes through rigorous testing before making it to the pharmacy shelf

Delivering when others fall short

  • No supply disruption vs. 203 generic injectable shortages with other suppliers3

What important safety infomation should I know?

CONTRAINDICATIONS
None

WARNINGS AND PRECAUTIONS
EMERPHED® can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.

ADVERSE REACTIONS
Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.
To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
Can include: interactions that augment pressor effect; interactions that antagonize the pressor effect; guanethidine; rocuronium; epidural anesthesia; theophylline; cardiac glycosides.

OVERDOSAGE
Overdose of EMERPHED® can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

INDICATIONS AND USAGE
Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

For more information, see full Prescribing Information.

EPH-136-v1